6533b85afe1ef96bd12b89ba

RESEARCH PRODUCT

Ibandronic acid subsequent to raloxifene: Effect on bone metabolism and on cardiovascular risk factors

Juan J. TarínAntonio CanoMarta FerrerAna Castro

subject

medicine.medical_specialtymedicine.drug_classbusiness.industryVitamin Emedicine.medical_treatmentCardiovascular risk factorsObstetrics and Gynecologymedicine.diseaseGastroenterologyIbandronic acidGeneral Biochemistry Genetics and Molecular BiologyBone remodelingchemistry.chemical_compoundEndocrinologychemistryEstrogenInternal medicineHyaluronic acidmedicineRaloxifeneVaginal atrophybusinessmedicine.drug

description

s / Maturitas 81 (2015) 144–190 161 Materials andmethods: This randomized double-blind clinical trialwas carried out inAhvaz (Iran) fromAugust toDecember 2010. Forty postmenopausal women with symptoms of vaginal atrophy were randomly allocated to two groups to take vaginal suppositories of either 5mg hyaluronic acid sodium salt (n=20) or 1mg vitamin E (n=20) for 8 weeks. The symptoms of vaginal atrophy were evaluated by a self-assessed 4-point scale and the composite score was determined as none, mild, moderate, and severe in four periods. Results: The results showed that the symptoms were relieved significantly in both groups (P<0.001). The relief of symptomswas significantly superior in the hyaluronic acid group compared with the vitamin E group (P<0.05). Conclusion: Although both hyaluronic acid and vitamin E relieved the vaginal symptoms, improvements were greater in the hyaluronic acid group. Therefore, hyaluronic acid vaginal suppository is suggested forwomenwith vaginal atrophywho do notwant to or cannot take local estrogen treatment.

https://doi.org/10.1016/j.maturitas.2015.02.184